•    Navarrabiomed – Miguel Servet Foundation supports this innovative development by facilitating technology transfer

The European Institute of Innovation and Technology, through its health innovation programme (EIT Health), will finance the market launch of DIABYUDA, a technological innovation from the University Hospital of Navarra’s Endocrinology Department managed by Navarrabiomed – Miguel Servet Foundation. The development offers a digital platform to support healthcare professionals in treating patients with type 2 diabetes through personalised, evidence-based treatment plans, in collaboration with other specialities.

This initiative is led by Joaquín de Carlos Artajo, a doctor in the Endocrinology Department and beneficiary of the microINTENSIFICATIONS (mINT) programme at Navarrabiomed - FMS, who will lead the working team alongside the Technical Innovation Department and the Management Unit of the biomedical research centre. The team also collaborates with the University of Navarra Incubator and the University of Navarra Clinic. 
The project is part of the “Deep Tech Venture Builder 2025” call for proposals and has a budget of €85,714, 70% of which is co-financed. 
 
AI for precision medicine

According to the International Diabetes Federation, type 2 diabetes affects 1 in 9 adults, and more than 45% of patients present poor control despite treatment.
This chronic disease is frequently associated with comorbidities such as cardiovascular and renal diseases, hypertension, and dyslipidaemia (abnormal blood lipid levels), which makes clinical management increasingly complex and requires an intensive use of resources. 
In this context, DIABYUDA has emerged to offer a digital clinical decision support system designed to facilitate precision medicine that results in more personalised, evidence-based care. Specifically, the platform integrates multidisciplinary medical knowledge based on clinical guidelines from various specialities with artificial intelligence and clinical information to support pharmacological decision-making, and provides personalised diet and physical exercise plans for each patient. 
“The expected impact is threefold: improve clinical decision-making by professionals, improve metabolic control, reduce complications for patients and alleviate the burden on healthcare systems, making them more efficient and sustainable,’ says Joaquín de Carlos. 
 
Technology transfer 

EIT offers emerging companies that offer advanced technological solutions in the academic field the financial and training support they need to overcome the most common obstacles and launch onto the market in what is known as the “Death Valley” phase, ensuring their financial viability in the medium and long term.
In the 2025 call for proposals in health, 17 initiatives, 4 of them Spanish, have been supported, which aim to improve the quality of life of European citizens through healthcare innovation. The programme will advise teams on matters such as regulation, strategy, financing and protection of innovation to ensure this technology transfer.
 

From left to right: Mikel Rubio (NB), Ander Ernaga, María José Goñi, Emma Anda and Joaquín de Carlos (HUN), Javier Robledo (UN) and Javier Escalada (CUN). Not in the picture: Beatriz Pérez and Marina Galilea (NB).